Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2017 Available from: http://goldcopd.orgAccessed January 30, 2017
   Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• WedzichaJASinghDVestboJFORWARD InvestigatorsExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
   PubMed Web of Science ®Google Scholar
• PascoeSJLipsonDALocantoreNA phase III randomized controlled trial of single-dose triple therapy in COPD: the IMPACT protocolEur Respir J201648232033027418551
   PubMed Web of Science ®Google Scholar
• Bodzenta-LukaszykABuhlRBalintBLomaxMSpoonerKDissanayakeSFluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: A randomized, controlled, non-inferiority trial of efficacy and safetyJ Asthma2012491060107023102189
   PubMedGoogle Scholar
• AalbersRBrusselleGMcIverTGrotheBBodzenta-LukaszykAOnset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized studyAdv Ther20122995896923081745
   PubMed Web of Science ®Google Scholar
• Bodzenta-LukaszykADymekAMcAulayKMansikkaHFluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: An open-label, randomized studyBMC Pulm Med2011112821605396
   PubMed Web of Science ®Google Scholar
• Bodzenta-LukaszykAPulkaGDymekAEfficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhalerRespir Med201110567468221196104
   PubMed Web of Science ®Google Scholar
• CorrenJMansfieldLEPertsevaTBlahzkoVKaiserKEfficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthmaRespir Med201310718019523273405
   PubMed Web of Science ®Google Scholar
• NathanRAD’UrzoABlazhkoVKaiserKSafety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomized controlled trialBMC Pulm Med2012126723078148
   PubMed Web of Science ®Google Scholar
• Bodzenta-LukaszykAvan NoordJSchroder-BaboWMcAulayKMcIverTEfficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomized controlled trialCurr Med Res Opin20132957958823368897
   PubMed Web of Science ®Google Scholar
• KaiserKPertsevaTLong-term safety and efficacy of fluticasone propionate/formoterol fumarate combination therapy in patients with asthmaPrim Care Respir J201322A1A18
   PubMedGoogle Scholar
• MansurAHKaiserKLong-term safety and efficacy of fluticasone/formoterol combination therapy in asthmaJ Aerosol Med Pulm Drug Deliv20132619019923098325
   PubMed Web of Science ®Google Scholar
• PapiAMansurAHPertsevaTLong-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbationsJ Aerosol Med Pulm Drug Deliv201629434636127104231
   PubMed Web of Science ®Google Scholar
• PapiAJonesPWDalviPSMcAulayKMcIverTDissanayakeSThe EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPDInt J Chron Obstruct Pulmon Dis2015102431243826648706
   PubMed Web of Science ®Google Scholar
• EXACT-PRO InitiativeThe Exacerbations of Chronic Pulmonary Disease Tool (EXACT) User Manual Version 5BethesdaEvidera2013
   Google Scholar
• SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2016111413142427445468
   PubMed Web of Science ®Google Scholar
• JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJfor the TRISTAN study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• CalverleyPMKunaPMonsóEBeclomethasone/formoterol in the management of COPD: a randomized controlled trialRespir Med2010104121858186820965712
   PubMed Web of Science ®Google Scholar
• JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
   PubMed Web of Science ®Google Scholar
• SinghDKampschulteJWedzichaJAA trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbationsEur Respir J2013411121722653766
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood Eosinophils: A Bio-marker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary DiseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsSusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• SpencerSJonesPWTime course of recovery of health status following an infective exacerbation of chronic bronchitisThorax200358758959312832673
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJACalverleyPMBias due to withdrawal in long-term randomized trials in COPD: evidence from the TORCH studyClin Respir J201151444921159140
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• XuWColletJPShapiroSNegative impacts of unreported COPD exacerbations on health-related quality of life at 1 yearEur Respir J20103551022103019897555
   PubMed Web of Science ®Google Scholar
• LangsetmoLPlattRWErnstPBourbeauJUnderreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohortAm J Respir Crit Care Med2008177439640118048806
   PubMed Web of Science ®Google Scholar
• JonesPWLamarcaRChuecosFCharacterisation and impact of reported and unreported exacerbations: results from ATTAINEur Respir J20144451156116525234803
   PubMed Web of Science ®Google Scholar
• MackayAJDonaldsonGCPatelARSinghRKowlessarBWedzichaJADetection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT)Eur Respir J201443373574423988767
   PubMed Web of Science ®Google Scholar
• IyerASDransfieldMTSerum eosinophils as a COPD biomarker: ready for prime time?Lancet Respir Med20164534134327066738
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2016111413142427445468
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• SinDDWuLManSFThe relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literatureChest200512761952195915947307
   PubMed Web of Science ®Google Scholar
• WilkeSJonesPWMullerovaHOne-year change in health status and subsequent outcomes in COPDThorax201570542042525782757
   PubMed Web of Science ®Google Scholar
• SchmidtSAJohansenMBOlsenMThe impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort studyBMJ Open2014412e006720
   PubMed Web of Science ®Google Scholar
• NayaITombsLMullerovaHComptonCJonesPLong-term outcome following first clinically important deterioration in COPDEur Respir J201648Suppl 60A304
   Google Scholar
• SinghDCorradiMSpinolaMPetruzzelliSPapiAExtrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary diseaseNPJ Prim Care Respir Med2016261603027309985
   PubMed Web of Science ®Google Scholar
• FesticEScanlonPDIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Am J Respir Crit Care Med2015191214114825409118
   PubMed Web of Science ®Google Scholar
• YamauchiYYasunagaHHasegawaWEffect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPDInt J Chron Obstruct Pulmon Dis2016111403141127382276
   PubMed Web of Science ®Google Scholar
• Di MartinoMAgabitiNCasciniSOUTPUL Study GroupThe effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in ItalyCOPD201613329330226514912
   PubMedGoogle Scholar